Benchmark Research Announces New Shreveport Site
Benchmark Research has announced a new site located in Shreveport, Louisiana will bring the company to 9 sites total across the states of Texas, California, and Louisiana. This clinic will be Benchmark’s first to focus on In-patient and out-patient psychiatric studies as well as groundbreaking studies with Cannabis and Psychedelics such as LSD, Psilocybin, Ketamine, MDMA, and others.
Benchmark Shreveport (SHV) will be spearheaded by Brian Wooten, the prior owner of the clinic. Brian is a CCRC with a master’s degree in clinical psychology. In the past 27 years throughout his career, he has held various positions in psychiatric medicine management including 25 years in various roles in psychiatric clinical research from CRC to site owner.
Read more about the new clinic here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
